Trending

24/7 MN – Aditxt, Inc. (NASDAQ: ADTX) Gaining on Preclinical Toxicity Study Success

(24/7 MARKET NEWS) – Aditxt, Inc. (NASDAQ: ADTX) shares are gaining in this morning’s premarket, at $0.225, up $0.065 (+40.69%), on 4.7 million shares traded.

Aditxt reported successful completion of a toxicology study that indicates the safety profile of ADI™-100, the Company’s immunotherapeutic technology drug that addresses rejection of transplanted organs, skin allografting, autoimmune diseases and allergies.

Aditxt, Inc. Successfully Completes Preclinical Toxicity Study of Its Psoriasis Drug Candidate ADI™-100 Advancing it Closer to First-in-Human Trials

https://www.bdtonline.com/news/nation_world/aditxt-inc-successfully-completes-preclinical-toxicity-study-of-its-psoriasis-drug-candidate-adi–100/article_b2457518-28d2-549b-9607-ec243557a91b.html

RICHMOND, Va.–(BUSINESS WIRE)–Jul 8, 2022– Aditxt, Inc. (Nasdaq: ADTX) (“Aditxt” or the “Company”), a biotech innovation company developing and commercializing technologies focused on monitoring and reprogramming the immune system, today announces that its therapeutic program Adimune™, has successfully completed a toxicology study that indicates the safety profile of ADI™-100, the Company’s immunotherapeutic technology drug that addresses rejection of transplanted organs, skin allografting, autoimmune diseases and allergies.

RelatedNews

Signup today for free and be the first to get notified of breaking news.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

SIGN UP FOR OUR NEWSLETTER

Sign up for Breaking Alerts, our newsletter putting timely and updated stock and crypto markets news into your hands.

Add New Playlist